Labcorp Holdings Inc. $LH Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. lowered its stake in Labcorp Holdings Inc. (NYSE:LH) by 2.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,101,801 shares of the medical research company’s stock after selling 26,523 shares during the period. Alliancebernstein L.P. owned approximately 1.33% of Labcorp worth $316,283,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Caldwell Trust Co acquired a new position in shares of Labcorp in the 2nd quarter worth $25,000. Financial Gravity Companies Inc. purchased a new stake in shares of Labcorp during the second quarter valued at $26,000. Motco acquired a new position in shares of Labcorp in the 3rd quarter valued at $32,000. Hantz Financial Services Inc. boosted its position in shares of Labcorp by 48.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 40 shares during the period. Finally, Headlands Technologies LLC increased its stake in Labcorp by 300.0% in the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock worth $34,000 after purchasing an additional 96 shares in the last quarter. 95.94% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

LH has been the subject of a number of analyst reports. JPMorgan Chase & Co. upped their price objective on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Piper Sandler boosted their price target on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a report on Tuesday, February 24th. Weiss Ratings upgraded shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, February 10th. Finally, Robert W. Baird raised their price objective on shares of Labcorp from $313.00 to $326.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $304.82.

Insider Transactions at Labcorp

In other Labcorp news, EVP Jonathan C. Meltzer sold 87 shares of the business’s stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $290.42, for a total value of $25,266.54. Following the transaction, the executive vice president owned 2,782 shares in the company, valued at $807,948.44. The trade was a 3.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Der Vaart Sandra D. Van sold 548 shares of the company’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $284.91, for a total value of $156,130.68. Following the completion of the transaction, the executive vice president directly owned 2,579 shares in the company, valued at approximately $734,782.89. The trade was a 17.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 16,113 shares of company stock valued at $4,547,450 in the last three months. 0.84% of the stock is currently owned by insiders.

Labcorp Stock Performance

LH stock opened at $263.57 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42. The stock has a market cap of $21.72 billion, a P/E ratio of 25.20, a P/E/G ratio of 1.80 and a beta of 1.01. The firm has a 50 day simple moving average of $272.59 and a 200 day simple moving average of $269.85. Labcorp Holdings Inc. has a 52 week low of $209.38 and a 52 week high of $293.72.

Labcorp (NYSE:LH) last released its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 earnings per share for the quarter, beating the consensus estimate of $3.95 by $0.12. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The firm had revenue of $3.52 billion for the quarter, compared to analyst estimates of $3.56 billion. During the same quarter in the prior year, the business earned $3.45 EPS. The company’s revenue for the quarter was up 5.6% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Research analysts anticipate that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, March 12th. Stockholders of record on Friday, February 27th were paid a $0.72 dividend. The ex-dividend date of this dividend was Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. Labcorp’s dividend payout ratio is 27.53%.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.